Use of carperitide infusion for acutely decompensated heart failure

1] recently reported in their meta-analysis that carperitide infusion improved the renal function of cardiovascular surgical patients, and we feel that this notion could be expanded to medical patients, particularly with the use of carperitide. Although some studies have not been able to recommend the use of nesiritide in acute heart failure (HF) patients [2,3], more recent clinical trials have demonstrated a favorable eff ect of carperitide on ventricular remodeling and neurohormonal systems [4,5]. In our own series of acute HF patients (N = 371), carperitide was given to 135 patients (36.4%) and it was more frequently used in patients with higher New York Heart Association functional class (30.4 versus 15.7%, P < 0.01), prominent signs of HF, such as S3 heart sound In agreement with the analysis performed by Mitaka and colleagues, patients on carperitide had a higher rate of improvement in functional class (96.0 versus 67.9%, P < 0.01) during the hospital course. Importantly, there was no worsening of the mortality and/or HF rehospitalization rate in the carperitide treatment group compared to the non-carperitide group (29.1 versus 25.4%, P = 0.29) during the mean follow-up period of 1.7 years. Further, the use of carperitide was not associated with adverse events after adjustment for known predictors of HF, such as hypertension, diabetes, hyper-lipidemia, chronic kidney disease, and brain natriuretic peptide level at discharge (hazard ratio 1.13; P = 0.59). Carperitide compares favorably to nesiritide in several ways; it has a shorter half-life (2 minutes), does not mandate bolus infusion, and is used mostly as a single agent, not as an add-on drug to diuretics. We thus surmise that these unique pharmacological profi les may lead to diff erent outcomes and the use of carperitide should be judiciously evaluated in prospective trials. References 1. Mitaka C, Kudo T, Haraguchi G, Tomita M: Cardiovascular and renal eff ects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis. Eff ect of nesiritide in patients with acute decompensated heart failure. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Eff ects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac …